Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
Dear Doctor Letter (Rote-Hand-Brief) on Zaltrap® (aflibercept): Risk of osteonecrosis of the jaw
2016.03.17
Active substance: aflibercept
The company Sanofi-Aventis Deutschland GmbH is circulating information that cases of osteonecrosis of the jaw have been reported in cancer patients treated with Zaltrap®.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN